Advancements in Cancer Therapy with PRC2 Inhibitors
Author Information
Author(s): Wang Michael S., Sussman Jonathan, Xu Jessica A., Patel Reema, Elghawy Omar, Rawla Prashanth
Primary Institution: Hospital of the University of Pennsylvania
Hypothesis
Can pharmacological inhibitors of PRC2 improve cancer treatment outcomes?
Conclusion
PRC2 inhibitors like Tazemetostat, GSK126, and Valemetostat show promise in treating various cancers, but further research is needed to optimize their use.
Supporting Evidence
- Tazemetostat and GSK126 are effective against EZH2 mutations in lymphoma.
- Valemetostat shows potential as a dual inhibitor of EZH1 and EZH2.
- UNC1999 has demonstrated efficacy in drug-resistant cancer cell lines.
- Clinical trials indicate promising results for Tazemetostat in relapsed follicular lymphoma.
- GSK126 has shown limited effectiveness in human trials but remains a strong in vitro inhibitor.
- Valemetostat has been well tolerated in patients with relapsed T-cell lymphoma.
- EZH2 inhibitors may stabilize disease in aggressive cancer types.
Takeaway
Scientists are studying special medicines that can help fight cancer by targeting a protein called PRC2, which can either help or hurt cancer growth.
Methodology
A structured literature review was conducted using PubMed to identify relevant studies on PRC2 inhibitors.
Limitations
The review is limited to studies published in English and may not cover all relevant research on PRC2 inhibitors.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website